PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33158056-13	2020	While genomic mutations of SPOP can be treated with gene therapy, identification of AURKA as an upstream regulator of SPOP provides a powerful opportunity for retaining WT-SPOP in a vast majority of CRPC patients using AURKA inhibitors +- enzalutamide, thereby treating the disease and inhibiting its progression.	enzalutamide	239-251	aurora kinase A	Homo sapiens	84-89